| Статус: | Completed |
| Фаза: | не указано |
| Начало: | 1 октября 2016 г. |
| Окончание: | 25 декабря 2017 г. |
| Описание: | The purpose of this study is to evaluate the post-vaccination immune status at different time points in subjects immunized against Ebola Virus Disease; to select an optimal regimen of product administration; and, to assess safety of medicinal product GamEvac-Combi - Combined Vector-Based Vaccine against Ebola Virus Disease, 0.5 ml+0.5 ml/dose, following the immunization with a half (0.25 ml+0.25 ml/dose) and full (0.5 ml+0.5 ml/dose) therapeutic doses. |
| смотреть на ClinicalTrials.gov |
| Статус: | Completed |
| Фаза: | не указано |
| Начало: | 1 октября 2016 г. |
| Окончание: | 25 декабря 2017 г. |
| Описание: | The purpose of this study is to evaluate the post-vaccination immune status at different time points in subjects immunized against Ebola Virus Disease; to select an optimal regimen of product administration; and, to assess safety of medicinal product GamEvacVector-Based Vaccine against Ebola Virus Disease, 0.5 ml+0.5 ml/dose, following the immunization with a half (0.25 ml+0.25 ml/dose) and full (0.5 ml+0.5 ml/dose) therapeutic doses. |
| смотреть на ClinicalTrials.gov |
| Статус: | Completed |
| Фаза: | Phase 3 |
| Начало: | 10 июля 2013 г. |
| Окончание: | 2 декабря 2015 г. |
| Описание: | The purpose of the study is to demonstrate the noninferiority of Algeron in combination with ribavirin compared to Pegasys in combination with ribavirin in the treatment of chronic hepatitis C. |
| смотреть на ClinicalTrials.gov |